As reported recently, administration of SB-431542 (a strong inhibitor of the TGF-β type 1 receptor) delays ALS disease progression, indicating that the induction of TGF-β signaling has a detrimental effect [36]. This evidence concerns the gene TGFB1 and amyotrophic lateral sclerosis.